Summit Therapeutics (SMMT) FCF Margin (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly FCF Margin came in at 3879.55% in Q3 2022, down 207962.0% YoY from N/an in Q3 2021, and up 53.27% on a QoQ basis from 8302.13% in Q2 2022.
Summit Therapeutics (SMMT) FCF Margin (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of FCF Margin data on file, last reported at 3879.55% in Q3 2022.
- Quarterly FCF Margin fell 207962.0% year-over-year to 3879.55% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 20823.18% (down 1731550.0% YoY) and the FY2022 annual result came in at 5986.67%, down 195720.0% from the prior year.
- FCF Margin improved to 3879.55% in Q3 2022, from 8302.13% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 0.8% in Q4 2019 to a low of 33903.51% in Q2 2021.
- A 5-year average of 5925.43% and a median of 3704.78% in 2021 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2021 — FCF Margin sank 2292645 bps — and 2022, when it soared 2560138 bps.
- Tracing SMMT's FCF Margin over 5 years: stood at 662.52% in 2018, then surged by 100 bps to 0.8% in 2019, then tumbled by 540879 bps to 4335.68% in 2020, then rose by 15 bps to 3704.78% in 2021, then dropped by 5 bps to 3879.55% in 2022.
- The last three FCF Margin figures came in at 3879.55% (Q3 2022), 8302.13% (Q2 2022), and 7744.8% (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -3,879.55% |
| Jun 30, 2022 | -8,302.13% |
| Mar 31, 2022 | -7,744.80% |
| Dec 31, 2021 | -3,704.78% |
| Sep 30, 2021 | -1,799.92% |
| Jun 30, 2021 | -33,903.51% |
| Mar 31, 2021 | -10,785.42% |
| Dec 31, 2020 | -4,335.68% |
| Sep 30, 2020 | -9,315.47% |
| Jun 30, 2020 | -10,977.06% |
| Mar 31, 2020 | -2,661.06% |
| Dec 31, 2019 | -0.80% |
| Mar 31, 2019 | -2,178.13% |
| Oct 31, 2018 | -662.52% |
| Jul 31, 2018 | -25.62% |
| Apr 30, 2018 | -180.20% |
| Jan 31, 2018 | -275.74% |
| Oct 31, 2017 | -401.97% |
| Jul 31, 2017 | 200.53% |
| Apr 30, 2017 | -476.39% |